Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.
Publication
, Conference
Nghiem, P; Bhatia, S; Lipson, EJ; Sharfman, WH; Kudchadkar, RR; Friedlander, PA; Brohl, AS; Daud, A; Kluger, HM; Reddy, SA; Burgess, MA ...
Published in: Journal of Clinical Oncology
May 20, 2018
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
9506 / 9506
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Friedlander, P. A., … Topalian, S. L. (2018). Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. In Journal of Clinical Oncology (Vol. 36, pp. 9506–9506). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.9506
Nghiem, Paul, Shailender Bhatia, Evan J. Lipson, William Howard Sharfman, Ragini Reiney Kudchadkar, Philip Adam Friedlander, Andrew Scott Brohl, et al. “Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.” In Journal of Clinical Oncology, 36:9506–9506. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.9506.
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Friedlander PA, et al. Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 9506–9506.
Nghiem, Paul, et al. “Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 9506–9506. Crossref, doi:10.1200/jco.2018.36.15_suppl.9506.
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Friedlander PA, Brohl AS, Daud A, Kluger HM, Reddy SA, Burgess MA, Hanks BA, Olencki T, Boulmay BC, Lundgren LM, Ramchurren N, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 9506–9506.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
9506 / 9506
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences